MediPharm Labs Corp
LABS
Company Profile
Business description
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Contact
151 John Street
BarrieONL4N 2L1
CANT: +1 705 719-7425
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
161
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.70 | 31.80 | -0.35% |
| CAC 40 | 7,800.88 | 33.70 | -0.43% |
| DAX 40 | 23,970.36 | 247.14 | -1.02% |
| Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
| FTSE 100 | 9,081.44 | 38.87 | -0.43% |
| HKSE | 25,313.22 | 248.91 | -0.97% |
| NASDAQ | 21,178.58 | 70.27 | 0.33% |
| Nikkei 225 | 40,655.54 | 342.73 | -0.84% |
| NZX 50 Index | 12,893.53 | 17.21 | -0.13% |
| S&P 500 | 6,389.77 | 1.13 | 0.02% |
| S&P/ASX 200 | 8,670.40 | 27.30 | -0.31% |
| SSE Composite Index | 3,598.40 | 0.46 | 0.01% |